Clinical features and prognostic model for extranasal NK/T-cell lymphoma

European Journal of Haematology

Volumn 89, Issue 2, 2012, Pages 103-110

  Jo, Jae Cheol ^a   Yoon, Dok Hyun ^a   Kim, Shin ^a   Lee, Bong Jae ^a   Jang, Yong Ju ^a   Park, Chan Sik ^a   Huh, Jooryung ^a   Lee, Sang Wook ^a   Ryu, Jin Sook ^a   Suh, Cheolwon ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Extranasal sites; Extranodal NK T cell lymphoma; International Prognostic Index; Korean Prognostic Index; Prognosis

Indexed keywords

ADULT; ARTICLE; BONE MARROW; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KOREA; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 84863815465     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01796.x     Document Type: Article

References (29)

1. Chan JKCQ-ML, Ferry JA, Peh SC. Extranodal NK/T-cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:285-8.
2. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612-8.
3. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009;113:3931-7.
4. Pathologists LSGoJ. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 2000;50:696-702.
5. Ko Y-H, Kim C-W, Park C-S, Jang H-K, Lee S-S, Kim S-H, et al. REAL classification of malignant lymphomas in the republic of korea. Cancer 1998;83:806-12.
6. Au W-Y, Ma S-Y, Chim C-S, Choy C, Loong F, Lie AKW, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005;16:206-14.
7. Pagano L, Gallamini A, Trape G, Fianchi L, Mattei D, Todeschini G, et al. NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey. Ann Oncol 2006;17:794-800.
8. Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997;89:4501-13.
9. Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, Yang SH, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005;41:1402-8.
10. Suzuki R, Suzumiya J, Oshimi K. Differences between nasal and extranasal NK/T-cell lymphoma. Blood 2009;113:6260-1. author reply 1-2.
11. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30.
12. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010;21:1032-40.
13. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474-9.
14. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
15. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1.
16. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
17. Lim ST, Hee SW, Quek R, Lim LC, Yap SP, Loong EL, et al. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis. Eur J Haematol 2008;80:55-60.
18. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004;103:216-21.
19. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002;54:182-90.
20. Huang JJ, Zhu YJ, Xia Y, Zhao W, Lin TY, Jiang WQ, et al. A novel prognostic model for extranodal natural killer/T-cell lymphoma. Med Oncol 2011 [Epub ahead of print].
21. Liang R. Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type. Br J Haematol 2009;147:13-21.
22. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005;19:2186-94.
23. Suzuki R, Takeuchi K, Ohshima K, Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol 2008;26:66-72.
24. Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995;76:2351-6.
25. Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 2007;139:532-44.
26. Kim SJ, Kim WS. Treatment of localized extranodal NK/T cell lymphoma, nasal type. Int J Hematol 2010;92:690-6.
27. Yong W, Zheng W, Zhu J, Zhang Y, Wang X, Xie Y, et al. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 2009;88:647-52.
28. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011;117:1834-9.
29. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011;29:4410-6.